An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or…
Scientists co-led by St. Jude Children’s Research Hospital have identified a potential therapeutic vulnerability in some forms of osteosarcoma. Published…
